The tal-1 proto-oncogene encodes a helix-loop-helix DNAbinding protein that has been implicated in the formation of T cell acute lymphoblastic leukemia (TALL) . Patients with TALL harbor structural rearrangements of tal-1 that result from either local DNA deletion or t(1 ;14)(p34;gll) chromosome translocation . By analyzing t(1;14)(p34;gll) chromosomes from a series ofpatients, we have now identified a discrete region of tal-1 wherein most of the translocation breakpoints occur. Moreover, mapping of tal-1 genomic DNA revealed that coding exons are situated on both sides of the t(1 ;14)(p34;gll) major breakpoint region . Hence, the translocated allele of tal-1 is truncated in a manner that reduces its amino acid coding potential .
Summary
The tal-1 proto-oncogene encodes a helix-loop-helix DNAbinding protein that has been implicated in the formation of T cell acute lymphoblastic leukemia (TALL) . Patients with TALL harbor structural rearrangements of tal-1 that result from either local DNA deletion or t(1 ;14)(p34;gll) chromosome translocation . By analyzing t(1;14)(p34;gll) chromosomes from a series ofpatients, we have now identified a discrete region of tal-1 wherein most of the translocation breakpoints occur. Moreover, mapping of tal-1 genomic DNA revealed that coding exons are situated on both sides of the t(1 ;14)(p34;gll) major breakpoint region . Hence, the translocated allele of tal-1 is truncated in a manner that reduces its amino acid coding potential .
T he tal-1 gene was identified upon analysis of t(1 ;14) (p34;gll), a chromosome translocation observed in the malignant cells of patients with T cell acute lymphoblastic leukemia (TALL)t (1-4). Although it is found in only 3% of these patients, t(1 ;14)(p34;gll) has been implicated as a causative factor of leukemogenesis based on its occurrence in unrelated patients and its exclusive association with TALL (5) . The translocation generates a reciprocal exchange of genetic material between chromosomes 1 and 14 with cytogenetic breakage in chromosomal bands lp34 and 14gll. Consequently, the tal-1 gene from chromosome 1 is transposed into the TCR-ac/S chain locus at 14gll, whereupon its expression is presumably altered in a manner that promotes the formation of TALL.
Two additional lines of evidence support the notion that tal-1 is a protooncogene that potentially contributes to the development of TALL. First, the tal-1 gene product is a member of the helix-loop-helix (HLH) family of DNA binding proteins (1, 6), several of which have been shown to specifically recognize core sequences of eucaryotic transcriptional enhancers (7) (8) (9) (10) . Although HLH proteins control diverse aspects of normal cell growth and differentiation, three members of this family (i.e., c-m)c, lyl-1, and E2A) have 'Abbreviations used in this paper: HLH, helix-loop-helix; mbr, major breakpoint region ; TALL, T cell acute lymphoblastic leukemia. also been implicated in human acute lymphoblastic leukemia (11) (12) (13) . Second, despite the infrequency of t(1;14)(p34;gll) translocation, we have recently shown that -25% of TALL patients harbor a site-specific 90-kb deletion (taM) of the tal-1 gene that is apparently undetectable by cytogenetic analysis (14) . Therefore, structural alteration oftal-1, either by t(1 ;14) (p34;gll) translocation or 0 deletion, represents the most common genetic lesion associated with human TALL.
The mechanism by which translocated alleles of tal-1 are activated in malignancy is not understood. To address this issue, we have analyzed the structures of t(1;14)(p34 ;gll) chromosome junctions from a series of TALL patients . In each of five cases, the translocation breakpoint on chromosome 1 occurred within a discrete 1-kb region of the tal-1 locus. Moreover, mapping of tal-1 genomic DNA revealed that coding exons are situated on both sides of the t(1;14)(p34;gll) major breakpoint region (mbr). Hence, the translocated allele of tal-1 is truncated in a manner that reduces its amino acid coding potential .
Materials and Methods
The Patients. Clinical features of the pediatric TALL patients (cases 1 and 2) and karyotypic studies of their leukemic cells have already been described (5) . The adult TALL patient (case 0) was a 42-yr-old male with marked hyperleukocytosis comprised ofleu-kemic lymphoblasts . Cytogenetic analysis of his bone marrow lymphoblasts revealed an abnormal karyotype: 46,XYdel(6)(g11q21), t(1;14)(p34 ;g11). Leukemic cells analyzed in this report were derived from peripheral blood obtained just before treatment. The original designation of the t(1;14) translocation described a breakpoint in the p32 band of chromosome 1 (1); with improved karyotypic resolution of additional cases, we nowbelieve that the breakpoint lies in the proximal portion of p34 rather than in p32 (5).
DNA Analysis and Cloning. DNAs extracted from leukemic specimens were analyzed by Southern hybridization with radiolabeled DNA probes (15) . Genomic DNA libraries of BamHI-digested leukemic DNA were constructed in phage vector X2001, and re-
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Alteration of tal-1 and Human T Cell Leukemia striction fragments of recombinant X DNA were subcloned into plasmid and M13 phage vectors (15) . Nucleotide sequence analyses were performed on M13 single-stranded templates by the chain terminator method (16) .
Results and Discussion
In a recent cytogenetic study, the t(1;14)(p34 ;g11) translocation was observed in 5 of 168 children with TALL (5). We previously characterized translocationjunctions from two of these patients (cases 4 and 5), and found that the chromo- some 1 breakpoints occurred 1 kb apart at positions Nil and N12 kb, respectively, upstream of genomic sequences encoding the tal-1 HLH domain (see Fig. 1 C) (1) . To determine whether this region represents a common site ofchromosome translocation, we have analyzed t(1 ;14)(p34;g11) leukemic DNAs from an adult TALL patient (case 0) and two additional pediatric patients (cases 1 and 2). As shown in Fig. 1 A, patients 0 and 2 both exhibit a rearranged 12.2-kb BamHI fragment upon Southern hybridization with the tal-1 DNA probe B2EE-2 .0. Moreover, rearranged fragments of identical size were also detected in these patients by hybridization with a DNA probe (R28EX-4 .9) from the JS region of the TCR-a/8 chain gene (Fig. 1 B) . Therefore, X phage libraries ofBamHI-digested leukemic DNAs from patients 0 and 2 were constructed, and recombinant clones containing the 12.2-kb fragments were isolated by simultaneous screening with B2EE-2 .0 and R28EX-4 .9. Since the rearranged 12.2-kb fragments contain sequences from both chromosome 1(B2EE-2 .0) and chromosome 14 (R28EX-4.9), they are likely to encompass the t(1;14)(p34 ;gll) junctions of patients 0 and 2. This was confirmed by restriction mapping and nucleotide sequence analysis of the recombinant clones (XSh from patient 0; XS from patient 2), which revealed that the rearranged fragments are comprised oftal-1 sequences juxtaposed with the TCR J81 gene segment (Fig. 1, C and D) .
As illustrated in Fig. 1 A, the tal-1 probe B2EE-2 .0 de- tects two rearranged BamHI fragments (14.1 and 4.3 kb) in leukemic DNA from patient 1. To determine whether either fragment represents a t(1 ;14)(p34;g11) junction, a X phage library of BamHI-digested DNA from patient 1 was constructed and screened with the B2EE-2.0 probe. In this manner, three hybridizing clones were obtained, each of which contained the rearranged 14.1-kb fragment. Restriction mapping and sequence analysis of one such clone (XA) revealed it to be comprised of B2EE-2.0 sequences (chromosome 1) juxtaposed with sequences from the CS region of the TCR-cx/S chain gene (chromosome 14) (Fig. 2) . Two abnormal chromosomes, der(1) and der (14) , are generated as a consequence of t(1 ;14)(p34;g11) translocation (5) . From the known orientation of the TCR-cx/S chain gene on chromosome 14, we can deduce that the t(1 ;14)(p34;g11) junctions of clones XS, XSh, and XA (Figs. 1 C and 2 A) are derived from the der(1) chromosomes of patients 2, 0, and 1, respectively. A genetic map of tal-1 is provided in Fig.  3 , and the der(1) breakpoints from these patients are illustrated along with those previously determined for patients 4 and 5. The t(1;14)(p34 ;g11) breakage in patient 1 occurs within sequences represented by the B2EE-2 .0 probe; hence, Southern analysis with this probe revealed two rearranged fragments in digests ofpatient 1 leukemic DNA (Fig. 1 A) , one ofwhich corresponds to the der(1) junction (i.e., the 14.1-kb BamHI fragment), while the other is likely to represent (14) junction (i.e., the 4.3-kb BamHI fragment) . Southern hybridization with the tal-1 probe SUM (Fig. 3) revealed DNA rearrangements corresponding to the der (14) junctions in leukemic DNA from each of the five patients (data not shown). Hence, in these patients, the t(1;14)(p34;g11) rearrangement is conservative with respect to chromosome 1; that is, the continuity of tal-1 was disrupted, but few, if any, tal-1 sequences were lost as a consequence ofthe translocation. In contrast, Southern analyses with probes located upstream of the chromosome 14 breakpoints (e.g., EH-2.0; Fig. 1 C) indicate that substantial portions of the TCR locus were lost from the translocated alleles (data not shown), in accord with previous studies of other chromosomes defects involving the TCR-ct/6 chain gene (17) .
As illustrated in Fig. 3 , the five t(1;14)(p34 ;g11) breakpoints described in our studies cluster within a 1-kb region located -11 kb upstream of sequences encoding the tal-1 HLH domain. Recently, t(1 ;14)(p34;g11) translocations from two additional patients were described at the molecular level (2-4) . Notably, t(1 ;14)(p34;g11) breakage in the TALL cell line Kd also occurs within the same region of tal-1 that is disrupted in patients 0, 1, 2, 4, and 5 (2). In contrast, the t(1;14)(p34;g11) breakpoint of DU.528, a cell line derived from a rare stem cell leukemia, lies within 3'-noncoding sequences (designated SCL or td-5) of the tal-1 transcription unit (3, 4) . In sum, six of the seven t(1 ;14)(p34;g11) translocations characterized 
to date feature breakage within what can be described as the major breakpoint region (mbr) of tal-1 .
Since t(1;14)(p34;g11) is observed in only 3% of TALL patients (5), alteration oftal-1 by chromosome translocation is clearly an uncommon factor in the formation of TALL. Nevertheless, we recently detected tumor-specific rearrangement ofthe tal-1 gene in -25% ofTALL patients, including those without apparent karyotypic lesions of chromosome 1 (14) . Surprisingly, the tal-1 rearrangements observed in different patients are nearly identical ; that is, they all result from a precise 90-kb deletion (designated talc) that arises independently in each patient by site-specific recombination (14) . It may be significant that the downstream endpoint of the tall deletion occurs just 1 kb upstream of the tal-1 mbr (see Fig . 3 ). Hence, tald deletion and t(1 ;14)(p34;g11) translocation are structurally analogous lesions in that both serve to remove upstream sequences from the body of the tal-1 gene.
To understand the effect of t(1 ;14)(p34;g11) translocation on tal-1 gene expression, it is necessary to localize the mbr with respect to the tal-1 transcription unit. Although the initiation site(s) of tal-1 transcription is not known, at least two distinct mRNA species have been identified by cDNA sequence analysis (1, 6). Both transcripts encode the tal-1 HLH domain but differ from each other in their 5' sequences . To determine the origin of these sequences, we examined tal-1 genomic DNA by Southern hybridization with oligonucle- axon rb
Alteration of tal-1 and Human T Cell Leukemia otide probes representing tal-1 cDNA sequences. These studies revealed that transcribed sequences of tal-1 are derived from at least four exons (provisionally designated la, Ib, 11, and III), the genomic positions and nucleotide sequences ofwhich are illustrated in Fig. 3 . The distinct tal-1 transcripts are apparently derived as a consequence of alternative RNA splicing, since one species (designated type A mRNA) includes exons Ia, 11, and III, while the other (type B mRNA) contains exons Ib, II, and III . The effect of t(1;14)(p34 ;gll) translocation on the expression of type B mRNA transcripts cannot be evaluated until its transcription start site is defined. Nevertheless, since the t(1;14)(p34;gll) mbr lies downstream ofexon la, it is clear that translocated alleles of tal-1 are usually truncated so as to preclude normal expression of type A transcripts (Fig. 3) .
Sequences encoding the tal-1 HLH domain are located within exon III at a position x+11 kb downstream of the t(1 ;14)(p34;gll) mbr (Fig. 3) . The cDNA sequences determined for type A and type B transcripts do not extend sufficiently 5' to include the initiator codons ofprotein synthesis (1, 6). Hence, known sequences within the upstream exons (la, lb, and II) also have amino acid coding potential. The existence of coding sequences within exon la is especially significant because this exon is removed from the tal-1 locus as a consequence of t(1 ;14)(p34;gll) translocation. . Moreover, the 90-kb deletion engendered by tah recombination also results in the removal ofexon la (14) . Consequently, the tat-1 gene alterations associated with TALL, whether they arise by t(1;14)(p34;gll) translocation or tald recombination, are structurally analogous lesions that eliminate normal expression of the type A mRNA protein product .
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The linkage between tal-1 gene truncation and TALL is unclear. Nevertheless, studies of other oncogenes that encode presumptive DNA binding proteins provide some intriguing precedents. For example, most oncogenically activated myb proteins are truncated in a manner that removes an NH2-terminal site for phosphorylation by casein kinase II; it has been proposed that the loss of this site promotes neoplasia by releasing Myb from normal physiological controls (18) . The studies of c-myc and lyl-1 may be especially relevant to the mechanism of tal-1 activation since these genes also encode HLH proteins implicated in human acute lymphoblastic leukemia . Protein translation from normal c-myc mRNA begins at either of two alternative sites in the same reading frame: a leucine codon (CUG) from exon 1 or a methionine codon (AUG) from exon 2. Hence, the normal c-myc gene encodes a 67-kd polypeptide initiated at leucine (c-Myc-1), as well as a 64-kd species initiated at methionine (c-Myc-2) . A nearly universal feature of oncogenically activated c-myc genes is the mutation or removal of exon 1 sequences necessary for production of c-Myc-1 (19). Loss of exon 1 coding sequences has also been implicated in the malignant activation of lyl-1 (12). Although the biochemical functions of sequences encoded by the upstream exons of c-myc, lyl-1, and tal-1 are not known, disruption of these sequences is clearly a common occurrence in human leukemogenesis. This is especially prominent in TALL, where >25% ofpatients bear altered alleles of tal-1 in which exon la is removed as a result of either t(1;14)(p34;gll) translocation or tald recombination .
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